Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmnicellMEX:OMCL 75 EV-to-EBIT is 44.90 as of Jul. 31, 2026, which is 40% below its 10-year median of 74.25. GuruFocus rates MEX:OMCL with a GF Score™ of 75/100 and a GF Value™ of MXN796.23. The stock has 6 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Omnicell ranks worse than 87.05% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Omnicell's Enterprise Value is MXN27,637 Mil.
Omnicell's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN616 Mil. Therefore, Omnicell's EV-to-EBIT for today is 44.90.
The historical rank and industry rank for Omnicell's EV-to-EBIT or its related term are showing as below:
MEX:OMCL'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1225.04 Med: 74.25 Max: 6347.25
Current: 47.1
During the past 13 years, the highest EV-to-EBIT of Omnicell was 6347.25. The lowest was -1225.04. And the median was 74.25.
MEX:OMCL's EV-to-EBIT is ranked worse than 87.05% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs MEX:OMCL: 47.10
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Omnicell's Enterprise Value for the quarter that ended in Mar. 2026 was MXN42,798 Mil.
Omnicell's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN616 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell EV-to-EBIT Related Terms
Omnicell EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Omnicell's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:OMCL vs HTFL, TDOC, OMDA: EV-to-EBIT Comparison
For the Health Information Services subindustry, Omnicell's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Omnicell's EV-to-EBIT falls into.
Omnicell's current Enterprise Value is MXN27,637 Mil.
Omnicell's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN616 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell (MEX:OMCL) has a EV-to-EBIT of 44.90 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Omnicell and its competitors. This is 40% below median its historical median of 74.25. According to the industry distribution chart, Omnicell ranks #410 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 87%.
Is Omnicell's EV-to-EBIT too high?
Omnicell's current EV-to-EBIT of 44.90 is 40% below median its 10-year median of 74.25. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. Omnicell's value of 44.90 is 183.5% above this industry median. Based on the distribution chart, Omnicell ranks #410 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Omnicell has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's EV-to-EBIT compare to HTFL and TDOC?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #410 out of 471 companies for EV-to-EBIT. This places Omnicell in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Omnicell's value of 44.90 is 183.5% above this benchmark. While the company's 10-year median is 74.25 vs. the industry median of 15.84, Omnicell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current EV-to-EBIT of 44.90 is 183.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current EV-to-EBIT is 44.90, which is 40% below median its own 10-year median of 74.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (MEX:OMCL) has a current EV-to-EBIT of 44.90. The stock's GF Value™ is MXN796.23, compared to a current price of MXN761.16 — trading 4.4% below its estimated fair value. The current EV-to-EBIT is 44.90, which is 40% below median its 10-year median of 74.25 and 183.5% above the Healthcare Providers & Services industry median of 15.84. Omnicell's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Omnicell (MEX:OMCL), the current EV-to-EBIT is 44.90 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (MEX:OMCL) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be undervalued.
The current stock price of MXN761.16 is trading 4.4% below its estimated GF Value™ of MXN796.23.
Key valuation signals for MEX:OMCL:
EV-to-EBIT: 44.90 (40% below median its 10-year median of 74.25)
GF Value™: MXN796.23 vs. price of MXN761.16 (4.4% below fair value)
Industry Position: 183.5% above the Healthcare Providers & Services median (#410 of 471)
No single metric tells the full story. See the MEX:OMCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
75GF Score
Get the complete analysis for MEX:OMCL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OMCL has been successfully added to your 
